Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1997 1
1998 3
1999 1
2000 1
2001 1
2002 2
2003 3
2004 6
2005 4
2006 5
2007 7
2008 7
2009 6
2010 5
2011 7
2012 10
2013 9
2014 12
2015 16
2016 16
2017 14
2018 19
2019 10
2020 23
2021 26
2022 17
2023 17
2024 17
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

222 results

Results by year

Filters applied: . Clear all
Page 1
Morbidity and mortality from ataxia-telangiectasia are associated with ATM genotype.
Micol R, Ben Slama L, Suarez F, Le Mignot L, Beauté J, Mahlaoui N, Dubois d'Enghien C, Laugé A, Hall J, Couturier J, Vallée L, Delobel B, Rivier F, Nguyen K, Billette de Villemeur T, Stephan JL, Bordigoni P, Bertrand Y, Aladjidi N, Pedespan JM, Thomas C, Pellier I, Koenig M, Hermine O, Picard C, Moshous D, Neven B, Lanternier F, Blanche S, Tardieu M, Debré M, Fischer A, Stoppa-Lyonnet D; CEREDIH Network Investigators. Micol R, et al. J Allergy Clin Immunol. 2011 Aug;128(2):382-9.e1. doi: 10.1016/j.jaci.2011.03.052. Epub 2011 Jun 12. J Allergy Clin Immunol. 2011. PMID: 21665257
Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease: the REACH4 study.
Locatelli F, Kang HJ, Bruno B, Gandemer V, Rialland F, Faraci M, Takahashi Y, Koh K, Bittencourt H, Cleary G, Rosko C, Li X, St Pierre A, Prahallad A, Diaz-de-Heredia C. Locatelli F, et al. Among authors: gandemer v. Blood. 2024 Nov 14;144(20):2095-2106. doi: 10.1182/blood.2023022565. Blood. 2024. PMID: 39046767 Clinical Trial.
NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients.
Simonin M, Vasseur L, Lengliné E, Lhermitte L, Cabannes-Hamy A, Balsat M, Schmidt A, Dourthe ME, Touzart A, Graux C, Grardel N, Cayuela JM, Arnoux I, Gandemer V, Huguet F, Ducassou S, Lhéritier V, Chalandon Y, Ifrah N, Dombret H, Macintyre E, Petit A, Rousselot P, Lambert J, Baruchel A, Boissel N, Asnafi V. Simonin M, et al. Among authors: gandemer v. Blood. 2024 Oct 10;144(15):1570-1580. doi: 10.1182/blood.2023023754. Blood. 2024. PMID: 38848537
Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study.
Zsiros J, Brugieres L, Brock P, Roebuck D, Maibach R, Zimmermann A, Childs M, Pariente D, Laithier V, Otte JB, Branchereau S, Aronson D, Rangaswami A, Ronghe M, Casanova M, Sullivan M, Morland B, Czauderna P, Perilongo G; International Childhood Liver Tumours Strategy Group (SIOPEL). Zsiros J, et al. Lancet Oncol. 2013 Aug;14(9):834-42. doi: 10.1016/S1470-2045(13)70272-9. Epub 2013 Jul 4. Lancet Oncol. 2013. PMID: 23831416 Free PMC article.
[A 2023 inventory in oncology news].
Bay JO, Auberger B, Bouleuc C, Cohen R, Delom F, Firmin N, Gandemer V, L'Allemain G, Magne N, De Nonneville A, Orbach D, Pellier I, Rodrigues M, Wislez M; pour le comité de rédaction du Bulletin du Cancer. Bay JO, et al. Among authors: gandemer v. Bull Cancer. 2024 Jan;111(1):18-32. doi: 10.1016/j.bulcan.2023.12.003. Epub 2024 Jan 5. Bull Cancer. 2024. PMID: 38184423 Review. French.
[A 2022 inventory in oncology news].
Bay JO, Bouleuc C, Caux C, Delom F, Firmin N, Gandemer V, L'Allemain G, Magné N, Orbach D, Robert J, Rodrigues M, Sabatier R, Thiery-Vuillemin A, Wislez M; Comité de rédaction du Bulletin du Cancer. Bay JO, et al. Among authors: gandemer v. Bull Cancer. 2023 Jan;110(1):19-31. doi: 10.1016/j.bulcan.2022.12.002. Epub 2022 Dec 16. Bull Cancer. 2023. PMID: 36529541 Review. French.
Therapeutic drug monitoring of imatinib - how far are we in the leukemia setting?
Buhl Rasmussen AS, Andersen CL, Weimann A, Yang T, Tron C, Gandemer V, Dalhoff K, Rank CU, Schmiegelow K. Buhl Rasmussen AS, et al. Among authors: gandemer v. Expert Rev Clin Pharmacol. 2024 Mar;17(3):225-234. doi: 10.1080/17512433.2024.2312256. Epub 2024 Feb 12. Expert Rev Clin Pharmacol. 2024. PMID: 38345044 Review.
[A 2021 inventory in oncology news].
Bay JO, Bouleuc C, Firmin N, Gandemer V, Magne N, Orbach D, Penel N, Rodrigues M, Thiery-Vuillemin A, Wislez M, L'Allemain G, Sabatier R, Robert J; comité de rédaction du Bulletin du Cancer. Bay JO, et al. Among authors: gandemer v. Bull Cancer. 2022 Jan;109(1):8-19. doi: 10.1016/j.bulcan.2021.12.003. Epub 2021 Dec 31. Bull Cancer. 2022. PMID: 34980367 Review. French.
[What should we remember from 2020?].
Bay JO, Andre T, Bouleuc C, Gandemer V, Magne N, Orbach D, Pellier I, Penel N, Rodrigues M, Thariat J, Thiery-Villemin A, Wisley M, L'Allemain G, Robert J; Comité de rédaction du Bulletin du cancer. Bay JO, et al. Among authors: gandemer v. Bull Cancer. 2021 Jan;108(1):55-66. doi: 10.1016/j.bulcan.2020.12.002. Epub 2021 Jan 6. Bull Cancer. 2021. PMID: 33419531 Review. French.
222 results